The VLDL and
chylomicron particles of these patients are large and appear to lack atherogenic potential.
These findings raised the possibility that insulin may also stimulate LRP1-specific uptake of
chylomicron remnants in the liver.
In the intestinal mucosa, retinyl palmitate is incorporated into the
chylomicron core where it is thought to remain during triglyceride hydrolysis [35, 178-180].
The sieve's place in the treatment of septic shock syndrome (due to TNF alpha and other inflammatory cytokines) from endotoxin activation of the reticulo-endothelial system, especially the liver macrophages (Kuppfer cells) being negated by infusion of
chylomicrons (21).
(5) The primary function of LPL is the hydrolysis of triglycerides of very-low-density lipoproteins (VLDLs) and
chylomicrons (CM), thereby delivering free fatty acids to muscle and adipose tissue for energy production or storage.
Key words:
chylomicron remnants, cholesterol, apoB, catechins, atherosclerosis
Fatty acid composition of an oral load affects
chylomicron size in human subjects.
Familial type III hyperlipoproteinemia is a genetic disorder in which the plasma concentrations of both cholesterol and triglycerides are elevated as a result of the accumulation of
chylomicron remnants and intermediate-density lipoproteins (IDL).
* Non-chylomicron-containing lipid species that may cause false-positive
chylomicron detection on lipoprotein analysis can be identified with additional fractionation of the body fluid by ultracentrifugation.
Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and
chylomicron remnants in men with visceral obesity.
Human gene therapy company Amsterdam Molecular Therapeutics (Euronext: AMT) announced on Wednesday data demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to markedly improve
chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal.
20 May 2011 - Netherlands-based human gene therapy company Amsterdam Molecular Therapeutics (AMS: AMT) reported today results from a long-term efficacy study of Glybera (alipogene tiparvovec) that showed improved
chylomicron metabolism could be used as a biomarker for increased lipoprotein lipase (LPL) activity in those patients missing the gene that produces this protein.
The in vitro effects of
chylomicron remnant and very low density lipoprotein remnant on platelet aggregation in blood obtained from healthy persons.
In particular, the company will provide an update on previously reported initial results from a long-term clinical study of Glybera that showed improved
chylomicron metabolism could show utility as a biomarker in LPLD patients.
According to the company, the current opinion at this time is a reflection of insufficient proof of clinical benefit of Glybera as a result of low patient numbers measured for
chylomicron handling for at least 12 months post treatment.
